Pharmas Market Video Gallery
Discussing whether a new $487M investment from the government will help speed up the production of the most important va...
Novartis is opening on Tuesday the country's first plant to produce flu vaccines using cell cultures. These vaccines are...
SPECIAL REPORT
MOST SHARED
- Garlic Price Rises Surpass Gold, Stocks in China
- Ritz-Carlton ?Struggling? in the US: President
- New-Home Sales Jump 6.2% To Highest Level in Over Year
- S&P Stocks Trading at New 52-Week Highs
- The Executive Job Search
- Judge Erases Couple's $525,000 Mortgage Payment
- US Plans to Reduce Emissions By 17% Within Next Ten Years
- Activision Prepares to Double Dip on ‘Modern Warfare 2’
- Half of Banks' Losses May Still Be Hidden: IMF Head
- Where Do Pardoned Turkeys Go?
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- S&P Stocks Trading at New 52-Week Highs
- AIG, Ex-CEO Greenberg Reach Pact to Settle Disputes
- Bank of America CEO Search May Extend Into 2010
- 'Cancer of Fraud' Permeates Health Care System: Critics
- US Mint to Suspend American Eagle Gold 1-Ounce Coins
- Judge Erases Couple's $525,000 Mortgage Payment
- For Many in US, It Will Be a Scaled-Down Holiday Season
- Where Do Pardoned Turkeys Go?
- Jobless Claims Below 500,000, Durable Orders Slip
- Activision Prepares to Double Dip on ‘Modern Warfare 2’
PHARMA'S MARKET VIDEO
» More
RSS FEED
» Help
powered by digg
Pharma's Market
Apr.26
11:35 AM ET
Thursday, 26 Apr 2007
Tamiflu Turnaround
![]() |
AP |
Roche today is announcing that it's cutting back production of Tamiflu. When bird flu stories and fears started reaching critical mass more than a year ago, Roche came under considerable criticism for not being able to make enough Tamiflu to meet the sudden spike in demand.
The drug has been shown to work in fighting off seasonal and avian flu strains, but there are scattered reports of patient resistance to Tamiflu. Roche responded by quickly expanding its worldwide manufacturing capacity. Soon after, it announced that it could make as much as 400 million courses of Tamiflu per year. (Gilead Sciences [GILD Loading... ()
But to date, Roche says it has received orders from governments, health agencies and corporations for a total of 215 million courses. So it's scaling back unless or until demand picks up. I suspect that could happen if or when an infected bird is confirmed to have shown up on North American shores.
GlaxoSmithKline [GSK Loading... ()
Questions? Comments?
© 2009 CNBC, Inc. All Rights Reserved
POPULAR PHARMA'S MARKET POSTS
MORE FROM CNBC
TOPIC : Pharmaceuticals









